Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies

Gynecologic Oncology

Volumn 112, Issue 3, 2009, Pages 605-609

  Fehm, T ^a   Beck, V ^a   Banys, M ^a   Lipp, H P ^a   Hairass, M ^b   Reinert, S ^b   Solomayer, E F ^a   Wallwiener, D ^a   Krimmel, M ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Adverse reactions; Bisphosphonates; Breast cancer; Osteonecrosis of the jaw

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE GLUCONATE; CLINDAMYCIN; CLODRONIC ACID; CORTICOSTEROID; IBANDRONIC ACID; MOUTHWASH; PAMIDRONIC ACID; PENICILLIN G; THALIDOMIDE; TRASTUZUMAB; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADULT; AGED; ALCOHOL ABUSE; ANEMIA; ARTICLE; BONE MARROW METASTASIS; BREAST CANCER; COMORBIDITY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DENTAL CARIES; DIABETES MELLITUS; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG INDUCED DISEASE; FEMALE; GYNECOLOGIC CANCER; HUMAN; INCIDENCE; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OBESITY; OSTEOPOROSIS; PERIODONTITIS; PRIORITY JOURNAL; RISK FACTOR; TOBACCO DEPENDENCE; TOOTH ABSCESS; TOOTH EXTRACTION; TOOTH PROSTHESIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMIDAZOLES; INCIDENCE; JAW; MIDDLE AGED; OSTEONECROSIS; RISK FACTORS;

EID: 60449095070     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.11.029     Document Type: Article

References (30)

1. Ledoux D., Hamma-Kourbali Y., Di Benedetto M., Foucault-Bertaud A., Oudar O., Sainte-Catherine O., et al. A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice. Anticancer Drugs 17 (2006) 479-485
2. Santini D., Caraglia M., Vincenzi B., Holen I., Scarpa S., Budillon A., et al. Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat. Clin. Pract. Oncol. 3 (2006) 325-338
3. Vincenzi B., Santini D., Dicuonzo G., Battistoni F., Gavasci M., La Cesa A., et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J. Interferon Cytokine Res. 25 (2005) 144-151
4. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62 (2004) 527-534
5. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Broadley K.E., and Johnston S.R. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327 (2003) 469
6. Rogers M.J., Watts D.J., and Russell R.G. Overview of bisphosphonates. Cancer 80 (1997) 1652-1660
7. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol. 19 (2008) 420-432
8. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 61 (2003) 1115-1117
9. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353 (2005) 99-102
10. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22 (2007) 1479-1491
11. Felsenberg D., Hoffmeister B., Amling M., Mundlos S., Seibel M.J., and Fratzl P. Onkologie: Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch. Ärztebl. 103 (2006) 2681-2682
12. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23 (2005) 8580-8587
13. Lin J.T., and Lane J.M. Bisphosphonates. J. Am. Acad. Orthop. Surg. 11 (2003) 1-4
14. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63 (2005) 1567-1575
15. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. Oral Maxillofac. Surg. 65 (2007) 2397-2410
16. Rizzoli R., Burlet N., Cahall D., Delmas P.D., Eriksen E.F., Felsenberg D., et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42 (2008) 841-847
17. Zarychanski R., Elphee E., Walton P., and Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am. J. Hematol. 81 (2006) 73-75
18. Tarassoff P., and Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J. Oral Maxillofac. Surg. 61 (2003) 1238-1239
19. Bertoldo F., Santini D., and Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat. Clin. Pract. Oncol. 4 (2007) 711-721
20. Pazianas M., Miller P., Blumentals W.A., Bernal M., and Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin. Ther. 29 (2007) 1548-1558
21. Wilkinson G.S., Kuo Y.F., Freeman J.L., and Goodwin J.S. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J. Natl. Cancer Inst. 99 (2007) 1016-1024
22. Pastor-Zuazaga D., Garatea-Crelgo J., Martino-Gorbea R., Etayo-Perez A., and Sebastian-Lopez C. Osteonecrosis of the jaws and bisphosphonates. Report of three cases. Med. Oral Patol. Oral Cir. Bucal 11 (2006) E76-79
23. Lenz J.H., Steiner-Krammer B., Schmidt W., Fietkau R., Mueller P.C., and Gundlach K.K. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. J. Cranio-Maxillo-Facial Surg. 33 (2005) 395-403
24. Purcell P.M., and Boyd I.W. Bisphosphonates and osteonecrosis of the jaw. Med. J. Aust. 182 (2005) 417-418
25. Wooltorton E. Patients receiving intravenous bisphosphonates should avoid invasive dental procedures. CMAJ 172 (2005) 1684
26. Migliorati C.A., Casiglia J., Epstein J., Jacobsen P.L., Siegel M.A., and Woo S.B. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J. Am. Dent. Assoc. 136 (2005) 1658-1668
27. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83-93
28. Jadu F., Lee L., Pharoah M., Reece D., and Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann. Oncol. 18 (2007) 2015-2019
29. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J. Oral Maxillofac. Surg. 63 (2005) 682-689
30. Ripamonti C., Maniezzo M., Cislaghi E., Campa T., Fagnoni E., Saibene G., et al. Application of preventive measures minimizes the occurrence of the osteonecrosis of the jaw (ONJ) in solid tumor patients with bone metastases treated with bisphosphonates: a single Institution series. Breast Cancer Res. Treat. 106 (2007) 2056